title: CNS relapse in a low risk acute promyelocytic leukemia patient treated with ATRA-based regimen: is there a role for prophylactic CNS therapy in acute promyelocytic leukemia?
abstract: Though the incidence of CNS relapse in acute promyelocytic leukemia (AML-M3 FAB classification) has increased following the advent of all-trans retinoic acid (ATRA), still CNS relapse accounts for only 2-3% of all relapses in AML-M3 trated with standard ATRA plus chemotherapy regimen. We report a case of low risk AML-M3 treated with standard therapy, developing CNS relapse while on maintenance therapy with ATRA + 6-mercaptopurine (6-MP) + methotrexate (MTX).
authors.affiliation: Department of Medical Oncology, Baby Memorial Hospital, Calicut, India.
authors.forename: K V
authors.initials: KV
authors.lastname: Gangadharan
authors.forename: Raghuveer
authors.initials: R
authors.lastname: Prabhu
authors.forename: Neena
authors.initials: N
authors.lastname: Mampilly
keywords: Acute promyelocytic leukemia; All-trans retinoic acid; CNS relapse; Prophylactic CNS therapy